In-stent restenosis: Pathophysiology and treatment

Current Treatment Options in Cardiovascular Medicine

Volumn 18, Issue 2, 2016, Pages

  Looser, Patrick M ^a   Kim, Luke K ^a   Feldman, Dmitriy N ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Bare metal stent; Coronary artery disease; Drug coated balloon; Drug eluting stent; In stent restenosis; Percutaneous coronary intervention

Indexed keywords

ACUTE HEART INFARCTION; ARTICLE; AUTOPSY; BARE METAL STENT; BRACHYTHERAPY; DRUG ELUTING STENT; HUMAN; IN-STENT RESTENOSIS; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RISK FACTOR; ROTATIONAL ATHERECTOMY; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

EID: 85008465366     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-015-0433-7     Document Type: Article

References (58)

1. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56:1897-907.
2. Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63:2659-73.
3. Brener SJ, Kereiakes DJ, Simonton CA, Rizvi A, Newman W, Mastali K, et al. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of subjects with de novo native coronary artery lesions trial. Am Heart J. 2013;166(6):1035-42.
4. Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, et al. Comparison of zotarolimusand everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8(6):e002230.
5. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100(18):1872-8.
6. Zhang BC, Karanasos A, Regar E. OCT demonstrating neoatherosclerosis as part of the continuous process of coronary artery disease. Herz. 2015;40(6):845-54.
7. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation. 2004;109(9):1085-8.
8. Lee SW, Lee JY, Ahn JM, Park DW, Han S, Park YK, et al. Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials). Am J Cardiol. 2013;112(11):1738-44.
9. Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-619.
10. American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, Society for Cardiovascular Angiography and Interventions, Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44-122.
11. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, et al. The pathology of neoatherosclerosis in human coronary implants baremetal and drug-eluting stents. J Am Coll Cardiol. 2011;57(11):1314-22.
12. Tada T, Kadota K, Hosogi S, Miyake K, Ohya M, Amano H, et al. Association between tissue characteristics assessed with optical coherence tomography and midterm results after percutaneous coronary intervention for in-stent restenosis lesions: a comparison between balloon angioplasty, paclitaxel-coated balloon dilatation, and drug-eluting stent implantation. Eur Heart J Cardiovasc Imaging. 2015;16(10):1101-11.
13. Jang JY, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, et al. Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation: qualitative optical coherence tomographic analysis. Atherosclerosis. 2015;242(2):553-9.
14. Goto K, Zhao Z, Matsumura M, Dohi T, Kobayashi N, Kirtane AJ, Rabbani LE, Collins MB, Parikh MA, Kodali SK, Leon MB, Moses JW, Mintz GS, Maehara A. Mechanisms and patterns of intravascular ultrasound instent restenosis among bare metal stents and firstand second-generation drug-eluting stents. Am J Cardiol. 2015.
15. Wakabayashi K, Mintz G, Delhaye C, Choi YJ, Doh JH, Ben-Dor I, et al. In vivo virtual histology intravascular ultrasound comparison of neointimal hyperplasia within drug-eluting- versus bare metal stents. J Invasive Cardiol. 2011;23(7):262-8.
16. Tocci G, Barbato E, Coluccia R, Modestino A, Pagliaro B, Mastromarino V, Giovannelli F, Berni A, Volpe M. Blood pressure levels at the time of percutaneous coronary revascularization and risk of coronary in-stent restenosis. Am J Hypertens. 2015.
17. Zhao LP, Xu WT, Wang L, Li H, Shao CL, Gu HB, et al. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drugeluting stent implantation after long-term angiographic follow-up. Coron Artery Dis. 2015;26 (1):5-10.
18. Magalhaes MA, Minha S, Chen F, Torguson R, Omar AF, Loh JP, et al. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations. Circ Cardiovasc Interv. 2014;7(6):768-76.
19. Rathore S, Kinoshita Y, Terashima M, Katoh O, Matsuo H, Tanaka N, et al. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents. Euro Interv. 2010;5(7):841-6.
20. Nam CW, Rha SW, Koo BK, Doh JH, Chung WY, Yoon MH, et al. Usefulness of coronary pressure measurement for functional evaluation of drug-eluting stent restenosis. Am J Cardiol. 2011;107(12):1783-6.
21. Park SJ, Kim KH, Oh IY, Shin DH, Park KI, Seo MK, et al. Comparison of plain balloon and cutting balloon angioplasty for the treatment of restenosis with drug- eluting stents vs bare metal stents. Circ J. 2010;74 (9):1837-45.
22. Song HG, Park DW, Kim YH, Ahn JM, Kim WJ, Lee JY, et al. Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation. J Am Coll Cardiol. 2012;59 (12):1093-100.
23. Takano M, Yamamoto M, Murakami D, et al. Optical coherence tomography after new scoring balloon angioplasty for in-stent restenosis and de novo coronary lesions. Int J Cardiol. 2010;141:e51-3.
24. Singh GD, Armstrong EJ, Laird JR. Femoropopliteal instent restenosis: current treatment strategies. J Cardiovasc Surg (Torino). 2014;55(3):325-33.
25. Byrne R. Intracoronary stenting and angiographic results: optimizing treatment of drug eluting stent instent restenosis 4—ISAR-DESIRE 4. Presented at TCT 2015, San Francisco.
26. O’Brien ER, Glover C, Labinaz M. Acute outcome with the flexicut directional coronary atherectomy catheter for the treatment of coronary in-stent restenosis. J Invasive Cardiol. 2001;13(9):618-22.
27. vom Dahl J, Dietz U, Haager PK, Silber S, Niccoli L, Buettner HJ, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). Circulation. 2002;105(5):583-8.
28. Alfonso F, Sandoval J, Nolte C. Calcified in-stent restenosis: a rare cause of dilation failure requiring rotational atherectomy. Circ Cardiovasc Interv. 2012;5(1): e1-2.
29. Oliver LN, Buttner PG, Hobson H, Golledge J. A metaanalysis of randomised controlled trials assessing drugeluting stents and vascular brachytherapy in the treatment of coronary artery instent restenosis. Int J Cardiol. 2008;126:216-23.
30. Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet. 2002;359:551-7.
31. Alli OO, Teirstein PS, Satler L, Sketch Jr MH, Popma JJ, Mauri L, et al. Five-year follow-up of the sirolimuseluting stents vs vascular brachytherapy for bare metal in-stent restenosis (SISR) trial. Am Heart J. 2012;163 (3):438-45.
32. Benjo A, Cardoso RN, Collins T, Garcia D, Macedo FY, El-Hayek G, et al. Vascular brachytherapy versus drug-eluting stents in the treatment of in-stent restenosis: a meta-analysis of long-term outcomes. Catheter Cardiovasc Interv. 2015. doi:10.1002/ccd.25998.
33. Mintz GS, Hoffmann R, Mehran R, Pichard AD, Kent KM, Satler LF, et al. In-stent restenosis: the Washington Hospital Center experience. Am J Cardiol. 1998;81 (7A):7E-13.
34. Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, López-Minguez JR, et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol. 2003;42 (5):796-805.
35. Alfonso F, Augé JM, Zueco J, Bethencourt A, López-Mínguez JR, Hernández JM, et al. Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study. J Am Coll Cardiol. 2005;46(5):756-60.
36. Alfonso F, Pérez-Vizcayno MJ, Hernandez R, Fernandez C, Escaned J, Bañuelos C, et al. Sirolimus-eluting stents versus bare-metal stents in patients with in-stent restenosis: results of a pooled analysis of two randomized studies. Catheter Cardiovasc Interv. 2008;72(4):459-67.
37. Alfonso F, Pérez-Vizcayno MJ, Hernández R, Bethencourt A, Martí V, López-Mínguez JR, et al. Longterm clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. J Am Coll Cardiol. 2008;52(20):1621-7.
38. Samady H, Mekonnen G. Drug-eluting balloons: effective and durable treatment for in-stent restenosis. JACC Cardiovasc Interv. 2013;6(6):577-9.
39. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355(20):2113-24.
40. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119(23):2986-94.
41. Indermuehle A, Bahl R, Lansky AJ, Froehlich GM, Knapp G, Timmis A, et al. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. Heart. 2013;99(5):327-33.
42. Xu B, Gao R, Wang J, Yang Y, Chen S, Liu B, et al. A prospective, multicenter, randomized trial of paclitaxel- coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv. 2014;7(2):204-11. Large randomized trial comparing DCB and 1st generation stents.
43. Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff B, Tiroch K, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013;381(9865):461-7.
44. Kufner S, Cassese S, Valeskini M, Neumann FJ, Schulz-Schüpke S, Hoppmann P, et al. Long-term efficacy and safety of paclitaxel-eluting balloon for the treatment of drug-eluting stent restenosis: 3-year results of a randomized controlled trial. JACC Cardiovasc Interv. 2015;8(7):877-84.
45. Habara S, Kadota K, Shimada T, Ohya M, Amano H, Izawa Y, et al. Late restenosis after paclitaxel-coated balloon angioplasty occurs in patients with drug- eluting stent restenosis. J Am Coll Cardiol. 2015;66 (1):14-22.
46. Scheller B, Fontaine T, Mangner N, Hoffmann S, Bonaventura K, Clever YP, et al. A novel drug-coated scoring balloon for the treatment of coronary in-stent restenosis: results from the multi-center randomized controlled PATENT-C first in human trial. Catheter Cardiovasc Interv. 2015. doi:10.1002/ccd.26216.
47. Miglionico M, Mangiacapra F, Nusca A, Scordino D, Gallo P, Campanale M, Melfi R, Di Sciascio G. Efficacy and safety of paclitaxel-coated balloon estenosis in high-risk patients. Am J Cardiol. 2015.
48. Kawamoto H, Ruparelia N, Latib A, Miyazaki T, Sato K, Mangieri A, et al. Drug-coated balloons versus second- generation drug-eluting stents for the management of recurrent multimetal-layered in-stent restenosis. JACC Cardiovasc Interv. 2015;8(12):1586-94.
49. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary instent restenosis: a randomized controlled trial. JAMA. 2005;293(2):165-71.
50. Alfonso F, Pérez-Vizcayno MJ, Hernandez R, Bethencourt A, Martí V, López-Mínguez JR, et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol. 2006;47(11):2152-60.
51. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García del Blanco B, García-Touchard A, López-Minguéz JR, et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV Randomized Clinical Trial. J Am Coll Cardiol. 2015;66[1]:23–33.
52. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B, Seidelberger B, Iñiguez A, et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial [Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent]. J Am Coll Cardiol. 2014;63[14]:1378–86.
53. Lee JM, Park J, Kang J, Jeon KH, Jung JH, Lee SE, et al. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials. JACC Cardiovasc Interv. 2015;8[3]:382–94.
54. Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-Vizcayno MJ, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386[9994]:655–64.
55. Alfonso F, Nuccio J, Cuevas C, Cárdenas A, Gonzalo N, Jimenez-Quevedo P. Treatment of coronary in-stent restenosis with bioabsorbable vascular scaffolds. J Am Coll Cardiol. 2014;63(25 Pt A):2875.
56. Deora S, Shah S, Pancholy S, Patel T. Bioresorbable vascular scaffold for coronary in-stent restenosis: a novel concept. Indian Heart J. 2014;66(4):459-61.
57. Pereira-da-Silva T, Patrício L, Cruz Ferreira R. Rotational atherectomy combined with bioresorbable vascular scaffold implantation: a feasible approach for recurrent in-stent restenosis when other therapies failed. J Invasive Cardiol. 2015;27(7):E143-5.
58. Murphy E, Boyle F. Reducing in-stent restenosis through novel stent flow field augmentation. Cardiovasc Eng Technol. 2012. doi:10.1007/s13239-012-0109-3.